Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis
NCT06941415Phase 3Recruiting
- Start
- Jun 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bumetanide in Cirrhosis (2 arms). Primary endpoint: Percent change in weight at 7 days. Started Jun 2026; status: recruiting.
02
Drugs
bumetanide
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT06941415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941415.